Total trials
240
Active
59
Phase 3
2
Total enrollment
2,077,875
Pipeline matrix
Showing 40 of 74 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Piflufolastat | — | — | — | — | — | 1 | |
| Fluciclovine PET/CT | — | — | — | — | — | 1 | |
| Immune Checkpoint Inhibitor | — | — | — | — | — | 1 | |
| Cytarabine | — | — | — | — | 12 | ||
| Prednisone | — | — | — | — | 5 | ||
| Venetoclax | — | — | — | — | 5 | ||
| Azacitidine | — | — | — | — | 3 | ||
| Obinutuzumab | — | — | — | — | 3 | ||
| Daunorubicin | — | — | — | — | 2 | ||
| Tremelimumab | — | — | — | — | 2 | ||
| methotrexate | — | — | — | 12 | |||
| Cyclophosphamide | — | — | — | 11 | |||
| Enzalutamide | — | — | — | 5 | |||
| Fluorouracil | — | — | — | — | 5 | ||
| Oxaliplatin | — | — | — | — | 5 | ||
| Pembrolizumab | — | — | — | — | 5 | ||
| Gemcitabine | — | — | — | — | — | 5 | |
| Paclitaxel | — | — | — | 4 | |||
| Fludarabine | — | — | — | — | — | 3 | |
| Leucovorin Calcium | — | — | — | — | 3 | ||
| Durvalumab | — | — | — | — | 3 | ||
| Capecitabine | — | — | — | 3 | |||
| irinotecan hydrochloride | — | — | — | — | — | 2 | |
| Ibrutinib | — | — | — | — | — | 2 | |
| Idarubicin | — | — | — | — | 2 | ||
| abiraterone acetate | — | — | — | — | 2 | ||
| Cladribine | — | — | — | — | — | 2 | |
| Doxorubicin | — | — | — | — | 2 | ||
| Cabazitaxel | — | — | — | — | 2 | ||
| Glofitamab | — | — | — | — | — | 1 | |
| Axatilimab | — | — | — | — | — | 1 | |
| Retifanlimab | — | — | — | — | — | 1 | |
| Gruticibart | — | — | — | — | — | 1 | |
| Olanzapine | — | — | — | — | — | 1 | |
| Amiodarone Hydrochloride | — | — | — | — | — | 1 | |
| Ulipristal Acetate | — | — | — | — | — | 1 | |
| Antiandrogen Therapy | — | — | — | — | — | 1 | |
| Apalutamide | — | — | — | — | — | 1 | |
| Mosunetuzumab | — | — | — | — | — | 1 | |
| Vincristine | — | — | — | — | — | 1 |
34 more active programs hidden
Next readouts
- 2019-10-16
- 2023-02-14
- 2024-06-10
- 2024-08-22
- 2024-09-25
- 2024-12-08
- 2025-12-16
- 2026-06-01
- 2026-12-01
- 2026-12-01
Top conditions
- Prostate Cancer15
- Leukemia13
- Breast Cancer12
- Prostate Carcinoma12
- Lymphoma12
- Malignant Solid Neoplasm12
- Breast Carcinoma9
- Myelodysplastic Syndromes8
Frequently asked questions about OHSU Knight Cancer Institute
- How many clinical trials does OHSU Knight Cancer Institute have on ClinicalTrials.gov?
- OHSU Knight Cancer Institute is listed as the lead sponsor on 240 clinical trials in ClinicalTrials.gov, 59 of which are currently active (recruiting, enrolling, or ongoing).
- How many of OHSU Knight Cancer Institute's trials are in Phase 3?
- 2 of OHSU Knight Cancer Institute's trials are in Phase 3, spread across 74 active drug programs.
- What therapeutic areas does OHSU Knight Cancer Institute focus on?
- OHSU Knight Cancer Institute's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Leukemia, Breast Cancer, Prostate Carcinoma, Lymphoma.
- When are OHSU Knight Cancer Institute's next clinical trial readouts?
- OHSU Knight Cancer Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer”, expected around 2019-10-16.